Plasma-activated medium suppresses choroidal neovascularization in mice: A new therapeutic concept for age-related macular degeneration

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Ye, Fuxiang ^a   Kaneko, Hiroki ^a   Nagasaka, Yosuke ^a   Ijima, Ryo ^a   Nakamura, Kae ^a   Nagaya, Masatoshi ^a   Takayama, Kei ^a   Kajiyama, Hiroaki ^a   Senga, Takeshi ^a   Tanaka, Hiromasa ^b   Mizuno, Masaaki ^c   Kikkawa, Fumitaka ^a   Hori, Masaru ^b   Terasaki, Hiroko ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; PLASMA GAS; REACTIVE OXYGEN METABOLITE;

ANIMAL; APOPTOSIS; CHEMISTRY; CHOROID; CHOROIDAL NEOVASCULARIZATION; DISEASE MODEL; ELECTRORETINOGRAPHY; HUMAN; MACULAR DEGENERATION; METABOLISM; MOUSE; PATHOLOGY; PLASMA GAS; RADIATION RESPONSE; RETINA;

ACETYLCYSTEINE; ANIMALS; APOPTOSIS; CHOROID; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; HUMANS; MACULAR DEGENERATION; MICE; PLASMA GASES; REACTIVE OXYGEN SPECIES; RETINA;

EID: 84949317289     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07705     Document Type: Article

References (47)

1. Ambati, J. et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 48, 257-293 (2003).
2. Bird, A. C. Therapeutic targets in age-related macular disease. J Clin Invest 120, 3033-3041 (2010).
3. de Jong, P. T. V. M. Mechanisms of disease: Age-related macular degeneration. New Engl J Med 355, 1474-1485 (2006).
4. Brown, D. M. et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New Engl J Med 355, 1432-1444 (2006).
5. Gragoudas, E. S., Adamis, A. P., Cunningham Jr, E. T., Feinsod, M., Guyer, D. R. Pegaptanib for neovascular age-related macular degeneration. New Engl J Med 351, 2805-2816 (2004).
6. Rosenfeld, P. J. et al. Ranibizumab for neovascular age-related macular degeneration. New Engl J Med 355, 1419-1431 (2006).
7. Kaneko, H. et al. Histamine receptor h4 as a new therapeutic target for choroidal neovascularization in age-related macular degeneration. Br J Pharmacol 171, 3754-3763 (2014).
8. Takeda, A. et al. CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature 460, 225-230 (2009).
9. Fridman, A. Plasma chemistry. (Cambridge University Press, 2008).
10. Yamazaki, H. et al. Microbicidal activities of low frequency atmospheric pressure plasma jets on oral pathogens. Dent Mater J 30, 384-391 (2011).
11. Fridman, G. et al. Applied plasma medicine. Plasma Process Polym 5, 503-533 (2008).
12. Morfill, G., Kong, M. G.&Zimmermann, J. Focus on plasmamedicine. New J Phys 11, 115011 (2009).
13. Yousfi, M., Merbahi, N., Pathak, A., Eichwald, O. Low-temperature plasmas at atmospheric pressure: toward new pharmaceutical treatments in medicine. Fundam Clin Pharmacol 28, 123-135 (2014).
14. Brun, P. et al.Disinfection of ocular cells and tissues by atmospheric-pressure cold plasma. PLoS One 7, e33245 (2012).
15. Fridman, G. et al. Blood coagulation and living tissue sterilization by floatingelectrode dielectric barrier discharge in air. Plasma Chem Plasma Process 26, 425-442 (2006).
16. Lee, H. W. et al. Tooth bleaching with nonthermal atmospheric pressure plasma. J Endod 35, 587-591 (2009).
17. Kim, C.-H. et al. Induction of cell growth arrest by atmospheric non-thermal plasma in colorectal cancer cells. J Biotechnol 150, 530-538 (2010).
18. Sato, T., Yokoyama, M., Johkura, K. A key inactivation factor of HeLa cell viability by a plasma flow. J Phys D Appl Phys 44, 372001 (2011).
19. Utsumi, F. et al. Effect of Indirect Nonequilibrium Atmospheric Pressure Plasma on Anti-Proliferative Activity against Chronic Chemo-Resistant Ovarian Cancer Cells In Vitro and In Vivo. PLoS One 8, e81576 (2013).
20. Vandamme, M. et al. Antitumor effect of plasma treatment on U87 glioma xenografts: preliminary results. Plasma Process Polym 7, 264-273 (2010).
21. Torii, K. et al. Effectiveness of plasma treatment on gastric cancer cells. Gastric Cancer 6, DOI: 10.1007/s10120-014-0395-6 (2014).
22. Iwasaki, M. et al. Nonequilibrium atmospheric pressure plasma with ultrahigh electron density and high performance for glass surface cleaning. Appl Phys Lett 92, 081503 (2008).
23. Jia, F. et al. Laser scattering diagnosis of a 60-hz non-equilibrium atmospheric pressure plasma jet. Appl Phys Express 4, 026101 (2011).
24. Iseki, S. et al. Selective killing of ovarian cancer cells through induction of apoptosis by nonequilibrium atmospheric pressure plasma. Appl Phys Lett 100, 113702-113704 (2012).
25. Tomida, D. et al. Suppression of choroidal neovascularization and quantitative and qualitative inhibition of VEGF and CCL2 by heparin. Invest Ophthalmol Vis Sci 52, 3193-3199 (2011).
26. Nishiguchi, K. M., Kataoka, K., Kachi, S., Komeima, K., Terasaki, H. Regulation of pathologic retinal angiogenesis in mice and inhibition of VEGF-VEGFR2 binding by soluble heparan sulfate. PLoS One 5, e13493 (2010).
27. Kaneko, H., Nishiguchi, K. M., Nakamura, M., Kachi, S., Terasaki, H. Characteristics of bone marrow-derived microglia in the normal and injured retina. Invest Ophthalmol Vis Sci 49, 4162-4168 (2008).
28. Tarallo, V. et al. DICER1 Loss and ,i.Alu,/i. RNA Induce Age-Related Macular Degeneration via the NLRP3 Inflammasome and MyD88. Cell 11, 847-859 (2012).
29. Kleinman, M. E. et al. Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3. Mol Ther 20, 101-108 (2011).
30. Miyata, K. et al. Reduction of oscillatory potentials and photopic negative response in patients with autosomal dominant optic atrophy with OPA1 mutations. Invest Ophthalmol Vis Sci 48, 820-824 (2007).
31. Ito, T. et al. Girdin and its Phosphorylation Dynamically Regulate Neonatal Vascular Development and Pathological Neovascularization in the Retina. Am J Pathol 182, 586-596 (2012).
32. Bid, H. K. et al. Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12. PLoS One 7, e35513 (2012).
33. Palomero, J. et al. SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. Blood 124, 2235-2247 (2014).
34. Arjunan, K. P. et al. Non-thermal dielectric barrier discharge plasma induces angiogenesis through reactive oxygen species. J Roy Soc Interface 9, 147-157 (2012).
35. Liang, F.-Q.&Godley, B. F. Oxidative stress-induced mitochondrialDNAdamage in human retinal pigment epithelial cells: a possible mechanism for RPE aging and age-related macular degeneration. Exp Eye Res 76, 397-403 (2003).
36. Miller, J. W. et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol 113, 810-818 (1995).
37. Solban, N. et al. Targeted photodynamic therapy. Lasers Surg Med 38, 522-531 (2006).
38. Oh, S. H., Lim, S. C. A rapid and transient ROS generation by cadmium triggers apoptosis via caspase-dependent pathway in HepG2 cells and this is inhibited through N-acetylcysteine-mediated catalase upregulation. Toxicol. Appl. Pharmacol 212, 212-223 (2006).
39. Zafarullah, M. et al. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 60, 6-20 (2003).
40. Hara, R. et al. Suppression of choroidal neovascularization by N-acetyl-cysteine in mice. Curr Eye Res 35, 1012-1020 (2010).
41. Lei, H. et al. N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy. Am J Pathol 177, 132-140 (2010).
42. Lebrun-Julien, F. et al. ProNGF induces TNFa-dependent death of retinal ganglion cells through a p75NTR non-cell-autonomous signaling pathway. Proc Natl Acad Sci USA 107, 3817-3822 (2010).
43. Remtulla, S.&Hallett, P.Aschematic eye for themouse, and comparisons with the rat. Vision Res 25, 21-31 (1985).
44. Sharma, S. et al. Pharmacological studies of themouse cone electroretinogram. Vis Neurosci 22, 631-636 (2005).
45. Yu, D.-Y., Cringle, S. J. Oxygen distribution in the mouse retina. Invest Ophthalmol Vis Sci 47, 1109-1112 (2006).
46. Michels, S. Is intravitreal bevacizumab (Avastin) safe Br J Ophthalmol 90, 1333-1334 (2006).
47. Simó, R.&Hernández, C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 51, 1574-1580 (2008).